<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00408187</url>
  </required_header>
  <id_info>
    <org_study_id>ISA05-25</org_study_id>
    <nct_id>NCT00408187</nct_id>
  </id_info>
  <brief_title>Randomized, Placebo and Ciclosporin Controlled Study of ISA247 in Plaque Psoriasis Patients</brief_title>
  <acronym>ESSENCE</acronym>
  <official_title>A Phase III, Randomized, Multicentre, Double-Blind, Placebo and Ciclosporin Controlled Study of ISA247 in Plaque Psoriasis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aurinia Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aurinia Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and efficacy of voclosporin in patients
      with plaque psoriasis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Psoriasis is a chronic skin condition that can have a significant impact on a patient's
      physical and mental well being. The most common form of psoriasis is plaque psoriasis.
      Targeted treatments in psoriasis have been reported recently, yet ciclosporin, a calcineurin
      inhibitor (CNi) remains one of the treatments which has the greatest efficacy. Voclosporin
      represents the possibility of a calcineurin inhibitor which is not only as efficacious as
      ciclosporin A, but also has an improved toxicity profile.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Superiority in the proportion of subjects achieving a score of &quot;clear&quot; or &quot;almost clear&quot; in the Static Physician's Global Assessment (SPGA) score</measure>
    <time_frame>Twelve weeks of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To show non-inferiority of voclosporin compared to ciclosporin in the proportion of subjects achieving a score of &quot;clear&quot; or &quot;almost clear&quot; in the Static Physician's Global Assessment (SPGA) score at</measure>
    <time_frame>Twelve weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Superiority in de novo hypertriglyceridemia, defined as proportion of patients developing fasting triglycerides greater than or equal to 1.7 mmol/L</measure>
    <time_frame>Twenty four weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Superiority in de novo hypertension, defined as proportion of patients developing blood pressure greater than or equal to 140 mmHg (systolic) or greater than or equal to 90 mmHg (diastolic)</measure>
    <time_frame>Twenty four weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Superiority of renal function, defined as the proportion of patients experiencing a confirmed greater than or equal to 30% rise in serum creatinine</measure>
    <time_frame>Twenty four weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Superiority in proportion of patients achieving a 75% reduction in the Psoriasis Area and Severity Index (PASI) score (PASI-75)</measure>
    <time_frame>Twelve weeks of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">642</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>1.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3.</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>voclosporin</intervention_name>
    <description>voclosporin 0.4 mg/kg po BID</description>
    <arm_group_label>1.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciclosporin</intervention_name>
    <description>ciclosporin 1.5 mg/kg po BID</description>
    <arm_group_label>2.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>3.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged greater than or equal to 18 years of age inclusive at time of screening.

          -  Diagnosed with plaque psoriasis greater than or equal to 6 months prior to screening.

          -  Diagnosis of stable, plaque psoriasis; i.e. psoriasis must not be spontaneously
             improving or worsening in the 4 weeks prior to the screening visit.

          -  Psoriasis failing at least one systemic treatment regimen or where other systemic
             therapies are contraindicated or where tolerability is an issue.

          -  Plaque psoriasis involving greater than or equal to 10% of the body surface area and a
             SPGA score greater than or equal to 3 at screening and prior to randomization at the
             day 0 visit.

          -  Not pregnant or nursing.

          -  Sexually active women of childbearing potential or less than 1 year post-menopausal
             and sexually active men who are not surgically sterile must use a reliable form of
             birth control during study treatment and for at least 3 months after the last dose of
             study drug. Surgically sterile females are not considered to be of childbearing
             potential. Reliable forms of birth control include oral or depot contraceptives, and
             double-barrier methods.

          -  Written informed consent prior to washout and screening procedures.

          -  Able to keep study appointments and cooperate with all study requirements, in the
             opinion of the Investigator.

        Exclusion Criteria:

          -  Has generalized erythrodermic, guttate, or pustular psoriasis.

          -  Have other dermatoses that would interfere with the evaluation of psoriasis, at the
             discretion of the Investigator.

          -  A current malignancy or history of malignancy within 5 years or a history of lymphoma
             at any time. Subjects can be enrolled with a history of squamous or basal cell
             carcinoma that has been surgically excised or removed with curettage and
             electrodesiccation.

          -  Has a current, uncontrolled bacterial, viral, or fungal infection that requires
             intravenous antibiotics or antifungals or has had such infections within 60 days prior
             to screening.

          -  A known history of tuberculosis.

          -  Serologic evidence or known latent HIV, HBV or HCV virus.

          -  Uncontrolled hypertension of systolic blood pressure greater than or equal to 160 mmHg
             or diastolic blood pressure greater than or equal to 90 mmHg.

          -  MDRD GFR &lt; 60 mL/min.

          -  Variation between the screening and Visit 1 SCr greater than or equal to 30%.

          -  ALT, AST, GGT greater than or equal to 2x upper limit of normal (ULN).

          -  White blood cell count less than or equal to 2.8 x 10 to the ninth power/L.

          -  Requires the following prohibited medications or treatments during the washout or
             treatment period: drugs potentiating the nephrotoxicity of voclosporin, drugs
             interfering with its pharmacokinetics, drugs considered to contribute to psoriasis
             flare; or, systemic and topical psoriasis medication that may interfere with
             assessment of study drug efficacy.

          -  Has used any investigational drug or device within 30 days or 10 half lives (whichever
             is longer) prior to the screening visit.

          -  Current participation in another clinical trial of any drug or biological agent.

          -  Has taken biological agent(s), except flu shots, tetanus shots, or boosters, within 3
             months of randomization. Biological agents include any virus, live vaccine,
             therapeutic serum, toxin, antitoxin, monoclonal antibodies or analogous product
             applicable to the prevention, treatment, or cure of diseases or injuries of man.

          -  Previous exposure to voclosporin.

          -  A history of clinically defined allergy to ciclosporin, constituents of Neoral or any
             of the constituents of the ISA247 formulation.

          -  A history of alcoholism or drug addiction.

          -  Weighs &lt; 45kg (99 lbs).

          -  A history of disease, including mental/emotional disorder that would interfere with
             the subject's participation in the study, in the evaluation of his/her response or
             that might cause the administration of voclosporin to pose a significant risk to the
             subject, in the opinion of the Investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wayne Gulliver, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>NewLab Clinical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vincent Ho, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UBC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrzej Langner, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>IWOLANG</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas A. Luger, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Muenster</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Slawomir Majewski, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Akademia Medyczna</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wolfram Sterry, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite Universitatsmedizin Berlin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5X 1X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3R 6A7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1B 3E1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1B 4F8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <zip>L4M 6L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N5X 2P1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <zip>L3P 1A8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>North Bay</city>
        <state>Ontario</state>
        <zip>P1B 3Z7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K2G 6E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2J 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2K 4L5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3H 1V4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1V 4X7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Ausburg</city>
        <zip>86179</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10435</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10437</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10827</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Bochum</city>
        <zip>44787</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Dresden</city>
        <zip>01097</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Geiβen</city>
        <zip>35390</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20354</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Lubeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Mahlow</city>
        <zip>15831</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Munster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Potsdam</city>
        <zip>14480</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Salzwedel</city>
        <zip>29410</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Wuppertal</city>
        <zip>42275</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Bialystock</city>
        <zip>15-540</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-096</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Gliwice</city>
        <zip>44-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Iwonicz Zdroj</city>
        <zip>38-440</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Krakow</city>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Lodz</city>
        <zip>91-347</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Lublin</city>
        <zip>02-080</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Poznan</city>
        <zip>60-355</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Szczcin</city>
        <zip>70-111</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02-008</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Warzszawa</city>
        <zip>02-008</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Zabrze</city>
        <zip>41-800</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>Poland</country>
  </location_countries>
  <reference>
    <citation>Gregory CR, Kyles AE, Bernsteen L, Wagner GS, Tarantal AF, Christe KL, Brignolo L, Spinner A, Griffey SM, Paniagua RT, Hubble RW, Borie DC, Morris RE. Compared with cyclosporine, ISATX247 significantly prolongs renal-allograft survival in a nonhuman primate model. Transplantation. 2004 Sep 15;78(5):681-5.</citation>
    <PMID>15371668</PMID>
  </reference>
  <reference>
    <citation>Stalder M, Bîrsan T, Hubble RW, Paniagua RT, Morris RE. In vivo evaluation of the novel calcineurin inhibitor ISATX247 in non-human primates. J Heart Lung Transplant. 2003 Dec;22(12):1343-52.</citation>
    <PMID>14672749</PMID>
  </reference>
  <reference>
    <citation>Abel MD, Aspeslet LJ, Freitag DG, Naicker S, Trepanier DJ, Kneteman NM, Foster RT, Yatscoff RW. ISATX247: a novel calcineurin inhibitor. J Heart Lung Transplant. 2001 Feb;20(2):161.</citation>
    <PMID>11250240</PMID>
  </reference>
  <reference>
    <citation>Bissonnette R, Papp K, Poulin Y, Lauzon G, Aspeslet L, Huizinga R, Mayo P, Foster RT, Yatscoff RW, Maksymowych WP; ISA247 Psoriasis Study Group. A randomized, multicenter, double-blind, placebo-controlled phase 2 trial of ISA247 in patients with chronic plaque psoriasis. J Am Acad Dermatol. 2006 Mar;54(3):472-8. Epub 2006 Jan 23.</citation>
    <PMID>16488299</PMID>
  </reference>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 4, 2006</study_first_submitted>
  <study_first_submitted_qc>December 4, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2006</study_first_posted>
  <last_update_submitted>July 29, 2009</last_update_submitted>
  <last_update_submitted_qc>July 29, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 30, 2009</last_update_posted>
  <responsible_party>
    <name_title>Robert Huizinga</name_title>
    <organization>Isotechnika</organization>
  </responsible_party>
  <keyword>Randomized Controlled Trials</keyword>
  <keyword>Immunosuppression</keyword>
  <keyword>Adult</keyword>
  <keyword>Chronic Disease</keyword>
  <keyword>Dermatologic Agents</keyword>
  <keyword>Female</keyword>
  <keyword>Humans</keyword>
  <keyword>Male</keyword>
  <keyword>Middle Aged</keyword>
  <keyword>Severity of Illness Index</keyword>
  <keyword>Treatment Outcome</keyword>
  <keyword>Quality of Life</keyword>
  <keyword>Double-Blind Method</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

